As of November 6, 2026, Allarity Therapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on June 2, 2026 (Form 8-K, June 2, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Allarity Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Allarity Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-06-02. Every row below is cited to the filing it comes from, and this page adds each new change as Allarity Therapeutics, Inc. files it.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-06-02 | Reported | not named in the filing | 8-K, 2026-06-02 |
Selling to them or working with them? See who runs Allarity Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Watch Allarity Therapeutics, Inc.
Get an email when Allarity Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Allarity Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Allarity Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Allarity Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
New leaders reset buying decisions — get the Full Report on Allarity Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Allarity Therapeutics, Inc., with the record behind each one.
Find candidates like senior executive at Allarity Therapeutics, Inc.Every change, in the filing's words
Reported
Termination for Convenience by the Company.
- Effective as of June 1, 2026 (the "A&R Effective Date"), the Company entered into an Amended and Restated Management Services Agreement (the "A&R MSA") with the Consultant.
- The A&R MSA amends and restates the Original MSA in its entirety.
- Except as described below, the material terms of the A&R MSA are substantially consistent with the material terms of the Original MSA previously disclosed by the Company.
- Under the A&R MSA, the Monthly Fee is payable in accordance with Attachment B to the A&R MSA, which provides that the Consultant's annual base salary for 2026 will be paid 80% in Swedish Krona and 20% in U.S. dollars, equal to SEK 6,000,000 and US$163,043.
- The A&R MSA eliminates the one-time $100,000 signing bonus provided under the Original MSA.
- The A&R MSA further provides that the Company shall endeavor to issue new annual bonus performance metrics on or before March 31 of each calendar year and, if no new metrics are issued by that date, the prior calendar year's bonus performance metrics will apply.
- The annual bonus will be capped at 60% of the Monthly Fees paid to the Consultant in a calendar year.
- If earned, any annual bonus is payable on or before March 15 following the end of the applicable calendar year.
- The A&R MSA increases the Company's notice period for a termination for convenience from 15 days to 30 days.
Tools for this story
Each opens in a new tab, filled in for Allarity Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.